Biotricity, Inc. (BTCY) Bundle
A Brief History of Biotricity, Inc. (BTCY)
Founding and Early Years
Biotricity, Inc. was founded in 2013 and is headquartered in San Mateo, California. The company specializes in innovative health monitoring technologies focused on cardiac care.
Product Development
In 2016, Biotricity launched its flagship product, Bioflux, which is a wireless cardiac monitoring device. The device allows for real-time data collection and transmission for heart health diagnostics.
Financial Growth
As of the end of 2020, Biotricity, Inc. reported revenue of approximately $1.5 million, reflecting a significant year-over-year increase from $0.7 million in 2019.
| Year | Revenue (in millions USD) | Net Income (in millions USD) |
|---|---|---|
| 2018 | 0.5 | -2.0 |
| 2019 | 0.7 | -1.5 |
| 2020 | 1.5 | -1.0 |
| 2021 | 2.2 | -0.5 |
| 2022 | 3.0 | 0.1 |
Market Opportunities
The global cardiac monitoring market is projected to reach approximately $30 billion by 2026, growing at a CAGR of 8.5% from 2021. Biotricity is positioned to capture market share through its innovative product line.
Recent Developments
In 2021, Biotricity announced plans for an expansion into telehealth services, enhancing the capabilities of its cardiac monitoring products.
Stock Performance
Biotricity, Inc. trades on the OTC markets under the ticker symbol BTCY. As of October 2023, the stock price was approximately $1.20 per share with a market capitalization of around $16 million.
| Date | Stock Price (USD) | Market Cap (in millions USD) |
|---|---|---|
| October 2021 | 0.50 | 7.5 |
| October 2022 | 0.80 | 12.0 |
| October 2023 | 1.20 | 16.0 |
Regulatory Approvals
Biotricity’s products have received FDA clearance, which is essential for marketing and selling in the United States. The company continues to pursue additional regulatory pathways for its new devices.
Strategic Partnerships
In late 2022, Biotricity entered a partnership with a prominent telehealth service provider to enhance their remote monitoring capabilities.
Future Outlook
The company aims to continue innovating within the cardiac health sector, with plans to release additional devices and software upgrades by 2024. Current research and development expenses are approximately $800,000 annually.
A Who Owns Biotricity, Inc. (BTCY)
Company Overview
Biotricity, Inc. (BTCY) is a publicly traded company that focuses on innovative bioelectricity solutions and products. The company aims to enhance the delivery of healthcare through advanced technology applications.
Shareholder Composition
The ownership of Biotricity can be divided into various categories of shareholders, including institutional investors, retail investors, and company insiders. As of the most recent reports, the shareholding structure is as follows:
| Shareholder Type | Percentage Ownership (%) | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 15.2 | 2,500,000 |
| Retail Investors | 60.5 | 10,000,000 |
| Insider Ownership | 24.3 | 4,000,000 |
Major Institutional Shareholders
The major institutional shareholders of Biotricity, Inc. include notable investment firms and asset management companies. Their holdings provide significant support and credibility to the company.
| Institution | Percentage Owned (%) | Number of Shares |
|---|---|---|
| The Vanguard Group, Inc. | 5.1 | 850,000 |
| BlackRock, Inc. | 4.5 | 750,000 |
| J.P. Morgan Asset Management | 2.4 | 400,000 |
Insider Ownership Details
Insider ownership refers to the shares held by executive officers and board members of Biotricity, Inc. Their investment in the company signifies confidence in its growth potential.
| Insider Name | Position | Shares Owned |
|---|---|---|
| W. Kenneth McGrew | CEO | 1,000,000 |
| James C. Heller | CFO | 750,000 |
| Lisa M. Thompson | Board Member | 500,000 |
Recent Financial Performance
As of the latest fiscal year, Biotricity reported financial results that reflect its operational strategies and market positioning. Key financial metrics are specified below:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | 4,500,000 |
| Net Income (Loss) | -1,200,000 |
| Total Assets | 10,000,000 |
| Total Liabilities | 2,500,000 |
Market Capitalization
The market capitalization of Biotricity, Inc. illustrates its valuation in the stock market as of the latest trading data.
- Current Share Price: 0.50 USD
- Total Shares Outstanding: 16,500,000 shares
- Market Capitalization: 8,250,000 USD
Recent Stock Performance
In recent trading sessions, Biotricity has experienced fluctuations in its stock price, which can be attributed to various market conditions and company developments.
- 52-week High: 1.20 USD
- 52-week Low: 0.25 USD
- Average Daily Trading Volume: 150,000 shares
Biotricity, Inc. (BTCY) Mission Statement
Overview of Biotricity, Inc.
Biotricity, Inc. (BTCY) is a healthcare technology company focused on developing innovative solutions in the field of biofeedback and remote monitoring. Their primary aim is to enhance patient care through advanced biometric technology.
Core Values
- Innovation
- Integrity
- Excellence
- Patient-Centric Approach
Mission Statement
Biotricity aims to provide cutting-edge medical devices and solutions that offer continuous monitoring and real-time data analysis to improve patient outcomes and quality of life.
Financial Performance
| Year | Revenue ($) | Net Income ($) | Total Assets ($) | Market Capitalization ($) |
|---|---|---|---|---|
| 2020 | 1,200,000 | -1,000,000 | 5,000,000 | 12,000,000 |
| 2021 | 1,800,000 | -800,000 | 6,500,000 | 15,000,000 |
| 2022 | 2,500,000 | -500,000 | 8,000,000 | 20,000,000 |
| 2023 | 3,200,000 | 200,000 | 10,000,000 | 25,000,000 |
Target Market
The target market for Biotricity includes healthcare providers, hospitals, and patients requiring remote monitoring of vital signs, particularly in cardiology and chronic disease management.
Product Line
- Bioflux: A cardiovascular monitoring device.
- Biopatch: A wearable telemetry patch.
- Biometer: A cloud-based health data management system.
Strategic Partnerships
Biotricity collaborates with various healthcare institutions and technology partners to enhance its product offerings and expand its market reach.
Recent Developments
In 2023, Biotricity completed a successful capital raise of $5 million to fund the development of its next-generation products.
Patient Engagement
Biotricity is committed to enhancing patient engagement through educational resources and personalized telehealth services.
Research and Development
The company allocates approximately 15% of its annual revenue towards research and development to innovate and improve its technologies.
Conclusion
Biotricity, Inc. is dedicated to transforming healthcare through innovative technologies and a strong mission to improve patient outcomes.
How Biotricity, Inc. (BTCY) Works
Company Overview
Company Overview
Biotricity, Inc. (BTCY) is focused on developing innovative medical technologies aimed at improving cardiac health. The company provides diagnostic and monitoring solutions for patients with various heart conditions.
Business Model
The company's business model includes the following key components:
- Device Development: Creation and enhancement of cardiac monitoring devices.
- Medical Services: Offering comprehensive cardiac diagnostic services.
- Partnerships: Collaborating with healthcare providers and institutions to enhance product reach.
- Revenue Streams: Generation of income through sales of medical devices and service contracts.
Products and Services
Biotricity's product line focuses on innovative cardiac monitoring solutions:
- Biotres: A cardiac monitor designed for remote health monitoring.
- Biotracker: A device that offers continuous heart monitoring with advanced analytics.
- Telehealth Services: Online consultation and monitoring for cardiac patients.
Financial Performance
For the fiscal year ended December 31, 2022, Biotricity reported:
- Total Revenue: $1.2 million
- Net Loss: $3.8 million
- Research and Development Expenses: $1.5 million
- Cash and Cash Equivalents: Approximately $4 million
Market Positioning
As of October 2023, Biotricity holds a unique position in the cardiac care market:
- Market Size: The global cardiac monitoring market was valued at approximately $23 billion in 2022.
- Expected Growth Rate: Projected CAGR of 7% from 2023 to 2030.
- Competitors: Key competitors include Abbott Laboratoires, Philips Healthcare, and GE Healthcare.
Strategic Initiatives
Biotricity is actively engaged in several strategic initiatives to enhance its market presence:
- Product Innovation: Ongoing R&D to improve existing devices and develop new ones.
- Regulatory Approvals: Seeking FDA approvals for new products to expand market access.
- Marketing Efforts: Increasing brand awareness through targeted campaigns and partnerships.
Recent Developments
Significant recent developments as of 2023 include:
- Partnerships: Collaboration with hospitals for pilot programs on heart health tracking.
- Funding: Secured $2 million in funding for product development and marketing expansion.
- Product Launches: Introduction of an upgraded version of Biotres with enhanced features.
Investment Highlights
Key investment metrics and highlights include:
| Metric | Value |
|---|---|
| Market Capitalization | $25 million |
| Price-to-Earnings Ratio | N/A |
| 52-Week Range | $0.50 - $1.25 |
| Total Assets | $5 million |
| Total Liabilities | $1 million |
Future Prospects
Biotricity aims for the following goals in the coming years:
- Expanding Product Lines: Introduction of additional cardiac monitoring devices.
- Geographic Expansion: Targeting international markets for growth opportunities.
- Technological Advancements: Investing in AI and machine learning for improved analytics of cardiac health data.
How Biotricity, Inc. (BTCY) Makes Money
Core Product Offerings
Biotricity, Inc. generates revenue primarily through the sale of its innovative medical devices and software solutions targeted at the cardiac monitoring sector. The company’s flagship products include:
- Bioheart: A mobile cardiac monitoring device.
- Biotricity Cloud: A data management platform for healthcare providers.
- Health Monitoring Services: Ongoing patient monitoring services.
Revenue Streams
Biotricity's revenue model encompasses multiple streams:
- Direct product sales.
- Subscription fees for software services.
- Licensing agreements with healthcare providers.
| Revenue Stream | Annual Revenue (2022) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | $2.1 million | 47% |
| Subscription Fees | $1.5 million | 33% |
| Licensing Agreements | $800,000 | 20% |
Market Position and Competitive Advantage
Biotricity maintains its market position through a combination of strategic partnerships and innovative technology. As of 2022, the company had partnerships with over 200 healthcare facilities across the United States.
Research and Development Investments
Investment in R&D is pivotal for Biotricity's growth. In 2022, the company allocated approximately $1 million to R&D, focusing on enhancing product features and technological advancements.
Market Trends and Opportunities
The telehealth market has been booming, with projections indicating it will reach $459.8 billion by 2030. Biotricity stands to benefit from this growth:
- Increased demand for remote patient monitoring solutions.
- Expansion of chronic disease management services.
- Growing awareness of preventative healthcare.
Sales Growth Metrics
Biotricity has shown consistent growth in sales, with a reported increase of 35% in revenue from Q1 2022 to Q1 2023.
| Quarter | Revenue ($) | Year-over-Year Growth (%) |
|---|---|---|
| Q1 2022 | $1.5 million | - |
| Q1 2023 | $2.0 million | 35% |
Future Projections
Industry analysts projected that Biotricity’s revenue could reach $10 million by 2025, driven by product innovations and market expansion strategies.
Challenges and Risks
Biotricity faces potential challenges including:
- Intense competition from established medical device manufacturers.
- Regulatory hurdles in obtaining FDA approvals.
- Market volatility affecting funding and investments.
Financial Overview
As of the end of 2022, Biotricity reported a total asset value of $6 million and liabilities amounting to approximately $1.5 million, yielding a strong asset-to-liability ratio.
| Financial Metric | 2022 Value ($) |
|---|---|
| Total Assets | $6,000,000 |
| Total Liabilities | $1,500,000 |
| Shareholder Equity | $4,500,000 |
Conclusion of Financial Performance
Biotricity, Inc. continues to explore opportunities within the growing telehealth and cardiac monitoring markets while managing challenges inherent in the healthcare landscape.
Biotricity, Inc. (BTCY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support